Seattle Genetics is a biotechnology company that creates and commercializes cutting-edge, empowered antibody-based therapies for treating cancer and other chronic illnesses. The effort to improvise cancer treatment is due to the increased late effects experienced by cancer survivors. The effects range from mild to severe. Other effects such as anemia improve or fade with time while some may be permanent like certain types of nerve damage. In many cases, medical experts cannot always procrastinate if the effects will occur.
Conventional cancer treatments are known for having late effects some cancer patients. Seattle Genetics is the market leader in antibody conjugates (ADCs) and strives to develop advanced cancer treatments. An antibody conjugate is a technology designed to control the targeting capability of monoclonal antibodies to produce cell-killing components. ADCs are aimed at sparing non-targeted cells hence minimizing most toxic effects of traditional chemotherapy, while possibly improving antitumor activity. In addition to the ADCs, the company is coming up with a large product offering to address unmet medical conditions.
Seattle Genetics was established in 1998 and has its corporate headquarters in Bothell, Washington. For almost 20 years, Seattle Genetics has developed designed monoclonal antibodies. The treatment has provided therapeutic benefit to cancer patients, people with autoimmune diseases and other chronic medical conditions. The antibody-based therapies have advanced cancer treatment by targeting malignant cells and preventing damage to normal tissues.
About Clay Siegall
Clay Siegall is the president, co-founder and chief executive officer of Seattle Genetics. He is a scientist by profession and has built Seattle Genetics on a foundation of thorough research, scientific advancement, and drug development practices. Dr. Siegall focuses on targeted cancer therapies due to his passion for helping clients.
Under Dr. Siegall‘s leadership, Seattle Genetics has attained its current leadership position in creating antibody-drug conjugates (ADCs) and the 2011 FDA approval of ADCETRIS® (brentuximab vedotin), the company’s first ADC product. He has also spearheaded the company’s capital-raising initiatives, raising more than $675 million through private and public financing.